What markers does Galleri use compared to OncuraKit?

Galleri (Grail Inc.) uses a very different approach. It analyzes cell-free DNA (cfDNA) methylation patterns from a blood draw across hundreds of thousands of genomic positions, using machine learning to classify whether the methylation pattern resembles cancer tissue versus normal tissue. Galleri does not directly measure miRNA. It requires PCR amplification and extensive bioinformatic analysis. Stage I sensitivity is 16.8% — meaning it misses more than 83% of early-stage cancers. OncuraKit measures three specific, extensively validated miRNA molecules from urine using single-molecule nanopore detection without amplification. Per-marker sensitivity is 81–97% at Stage I/II. OncuraKit produces a binary YES/NO result rather than a probabilistic cancer signal score. OncuraKit requires no blood draw and no prescription.